

# Index

- Absolute risk reduction (ARR) 88  
Accelerated failure time model 207–8, 210  
Adaptive designs 223–7  
Add-on trials 3  
Adjusted analysis 63, 91–110, 142, 246,  
247–8, 250, 253  
multiplicity 157  
survival data 204–8  
Adjusted significance level 148, 149–51,  
153, 155  
Allergic rhinitis 181  
Alpha error 127  
Alpha-spending functions 153, 214  
Alternative hypotheses 47, 59, 64, 93, 99  
equivalence 178–9  
Alzheimer's disease 23, 120  
Analysis of covariance (ANCOVA) 19, 63,  
91–110, 142  
ANOVA 101–2, 109  
assumptions 104, 159, 163  
baseline factors 97, 102–3, 110  
continuous data 97–104, 106, 109,  
204  
covariates 99–104, 108  
logistic regression 104–6  
non-parametric tests 169, 170  
survival data 194, 204  
transformations 164  
Analysis of variance (ANOVA) 19, 108,  
142, 204, 207  
ANCOVA 101–2, 109  
assumptions 159, 162  
non-parametric tests 169  
transformations 164  
*see also* Two-way analysis of variance  
Analysis sets 124–6, 246, 249, 250, 256  
ITT 115–18, 121  
multiplicity 148, 158  
Anti-infective trials 115, 116, 120, 137  
Arithmetic means 164  
Assumptions 114, 159, 160, 216, 246, 254–5  
ANCOVA 104, 159, 163  
homogeneity of variance 159, 160  
independent censoring 208–9  
non-inferiority 187–8  
non-parametric tests 168, 169, 170  
normality 159, 160–3, 166, 170  
proportional hazards 210  
sample size 138, 140, 162, 187–8  
t-tests 159, 160–3, 168, 170  
Asthma trials 15, 19, 43, 58, 107, 149–50  
Averages 27  
Back-transformations 164  
Balance 6, 8, 9–10, 61, 220  
Baseline factors 91–2, 109–10, 122, 125,  
223  
ANCOVA 97, 102–3, 110  
design 246  
DMCs 222  
interpreting t-tests 61–2  
logistic regression 96–7, 106  
multiple regression 94–6  
non-parametric tests 170  
publications 257  
randomisation 8–9, 10  
regulatory issues 106–8, 247–9  
sampling 26, 30, 133–4  
simple linear regression 92–4  
survival data 194, 204, 205–7  
Beta error 128

- Between-patient design 13, 52, 63, 77–8, 79
- Bias 11–12, 127, 137, 182, 238–40  
 adjusted analyses 102, 106, 108  
 design 3–4, 6, 8, 11–12, 21, 226, 245–6, 254  
 DMCs 220  
 intention-to-treat 113, 115–17, 118, 120, 122–4, 125–6  
 interim analysis 218  
 meta-analysis 238–40, 241–2  
 missing data 118, 120  
 paired t-test 61  
 publications 238–40, 260  
 randomisation 4, 6, 8, 12
- Binary data 18–19, 79, 88, 120, 181, 187  
 chi-square tests 63–7, 76, 77, 79, 88  
 CMH tests 91–2, 109, 204  
 design 18–19, 21, 23  
 logistic regression 96, 104–6, 109, 204, 205  
*p*-values and confidence intervals 45–6, 142, 145  
 sample size 29, 133, 136, 138, 187  
 treatment benefit measures 67–9, 76
- Biocreep 186–7
- Bioequivalence 14, 17, 173, 178, 182, 183
- Blind review 89, 106, 117, 158, 170, 251–2, 255
- Blinding 3–4, 89, 109, 223  
 design 1, 3–4, 5–6, 12, 223, 226, 245  
 DMCs 219–21  
 regulatory issues 248–9  
 sample size 138, 139  
*see also* Blind review; Unblinding
- Block randomisation 4, 5–6
- Blood pressure trials 25, 47
- Bonferroni correction 148, 151, 152–4, 155
- Breslow–Day test 88
- Cancer/oncology trials 7, 18–19, 23–4, 45
- Cardiovascular and myocardial infarction trials 18, 22, 73, 186
- Carry-over effect 14
- Case report forms (CRFs) 246
- Categorical data 18–19, 79, 88  
 chi-square tests 73–5, 76, 77, 79, 88  
 CMH tests 91–2  
 logistic regression 96, 97, 104–6  
 treatment benefit measures 76–7
- Categorisation 23–4
- Censored observations 193, 203
- Censoring 193–4, 208–9, 255  
 independent 208–9  
 survival data 193–4, 195–6, 200, 203, 206, 208–9
- Central Limit Theorem 30
- Central randomisation 4, 8–9
- Centre effects 157, 194, 204, 242, 248
- Chi-square distribution 65, 74
- Chi-square tests 19, 63–7, 71, 75–7, 79–80, 88  
 binary data 63–7, 76, 77, 79, 80, 88  
 categorical data 73–5, 76, 77, 79, 80, 88  
 extensions 77, 79, 80  
 Fisher's exact test 71–2  
 logistic regression 105  
 one degree of freedom test for trend 75  
 ordinal data 75–6, 77, 79, 80, 88
- Cholesterol trials 18, 22, 26–7, 44–5
- Clinical importance 143–5, 150–2, 216
- Clinically relevant difference (crd) 135–6, 216, 242  
 power 137  
 sample size 132–3, 135–6, 139, 189
- Cluster randomisation 4, 10–11
- Cochrane Collaboration 231
- Cochran–Mantel–Haenszel (CMH) test 88, 91–2, 109, 204
- Coin tossing 49–52, 56, 72, 127
- Combining centres 88–9
- Common odds ratio 77, 88
- Complete cases analysis 119
- Completers analysis 119
- Compliance 87, 107, 114–17, 181–2, 220
- Composite endpoints variables 23, 150, 226
- Conditional power 215–16, 223, 224
- Confidence coefficient 41–2, 46
- Confidence intervals 39–46, 70–1, 92, 141–4, 170, 175–80, 233  
 ANCOVA 99, 102, 104, 109  
 bioequivalence 183  
 clinical importance 143–4  
 design 10, 226  
 equivalence 175–6, 178–9, 180  
 logistic regression 104  
 meta-analysis 232–6, 241  
 multiple regression 96  
 non-inferiority 176–8, 179–80, 184, 187–90

- p*-values 58, 141–2, 143–5, 170, 178–80
- paired *t*-test 60
- sample size 42–4, 46, 187
- single mean 39–44
- standard errors 35, 38, 42, 43–4, 45, 70–1
- survival data 196, 201, 206
- transformations 164
- treatment benefit measures 67, 76–7
- unpaired *t*-test 58, 60
- Confirmatory trials 16–17, 118, 248, 250, 254
- Conflicts of interest 220–1
- Confounding 7
- Consistency 226–7
- CONSORT statement 139–40, 257–8
- Constancy 186–7
- Constant variance 159, 160, 164
- Continuous data 18–20, 29, 47, 82, 97–104
  - ANCOVA 97–104, 106, 109, 204
  - ANOVA 204
  - confidence intervals 45
  - covariates 107–8
  - meta-analysis 232
  - multiple regression 94–6
  - sample size 133, 135, 138, 140, 187
  - t*-tests 61, 63, 77–9, 83
  - two-way ANOVA 91, 109
- Control groups 2–3, 45, 78, 135, 253
  - bioequivalence 183
  - design 1–3, 12, 17–18
  - equivalence 17–18, 173, 180–1
  - non-inferiority 17–18, 173, 176, 180–1, 184–9, 191
  - regulatory issues 247, 249
  - treatment benefit measures 67–71
- Count data 19–20, 29, 45
- Covariates 82, 106–8, 110, 246
  - ANCOVA 99–104, 108
  - logistic regression 104–6
  - regulatory issues 106–8, 247–9
  - survival data 194, 204, 205, 207
- Critical value 52, 66
- Cross-over trials 12, 13, 14, 61, 78–9, 125
- Cross-product term 101, 105
- Cryptococcal meningitis trial 177–8, 190–1
- Cumulative incidence 197
- Cure rates 185–6, 188–9
- Data Monitoring Committees (DMCs) 218, 219–22, 224, 248
- Database lock 251, 252, 254
- Degrees of freedom 42–3, 58, 59, 95, 160
  - chi-square tests 65, 74, 76
- Dependence 93–4, 97, 104
- Depression trials 19, 122, 124, 181
- Design 1–24, 218, 223–7, 245–7, 248, 249, 254
  - regulatory issues 4, 17, 23, 247, 248–9
- Dirty data 252
- Dosage trials 47, 79–80, 174, 180–1, 231
  - design 3, 17
  - multiplicity 152, 154
- Double-blind trials 2, 4
- Dropouts 125–6, 180–1, 220, 224, 246, 253
  - missing data 120, 121, 125
  - sample size 139–40
- Dynamic allocation 4, 9–10
- Efficacy 214–15, 218, 219, 253
  - design 2, 4, 6, 11, 16–18, 21, 223–5
  - equivalence 17–18, 174
  - intention-to-treat 117, 124
  - multiplicity 149, 152–3
  - non-inferiority 17–18, 174, 176, 184–5, 186
  - regulatory issues 248–9, 256
  - stopping 214–15, 248
- Endpoints 20–4, 180–1, 187, 215, 249
  - see also* Primary endpoints; Secondary endpoints
- Epilepsy trials 19, 123–4, 194
- Equivalence margins 175–6, 182–3, 246
- Equivalence 17–18, 145, 173–6, 182–3, 189, 253
  - assay sensitivity 180–2
  - confidence intervals 175–6, 178–9, 180
  - design 17–18, 246
  - intention-to-treat 117
  - p*-values 145, 175, 178–80
- Ethics 17–18, 137, 174, 181, 217
- Event rates 135, 137, 196, 197, 231
  - sample size 137–8, 139
- Exclusion criteria 8, 25, 116, 125, 237
- Exercise duration trials 18, 22
- Expected frequencies (*E*) 64–6, 67, 72, 73, 75–6
- Exploratory trials 3, 16–17, 119, 139, 246, 250

F-test 157, 160  
 False negatives 128, 187  
 False positives 127, 140, 147–8, 187, 218, 242  
 Fisher's exact test 71–3, 75  
 Fixed effects model 234  
 Flexible designs 223–7, 248  
 Flu symptom trials 194, 199, 207–8  
 Follow-up 115, 121, 154, 216–17, 224  
   survival data 193–4, 196, 197, 209, 210–11  
 Forest plots 234  
 Full analysis set 137, 158, 182, 250  
   intention-to-treat 115–17, 118, 125–6  
   non-inferiority 182, 188, 190  
 Funnel plots 238–40  
 Futility 153, 215–16, 218, 224–5  
  
 Gaussian distribution 29–31  
 Gehan–Wilcoxon tests 194, 197–9, 204, 255  
 General alternative hypothesis 74, 77, 83, 85  
 Generalisability 81, 84, 87, 88  
 Generalised Wilcoxon test 197  
 Geometric means 164, 183  
 Global assessment variables 22, 23  
  
 Harm 214–15  
 Hazard rate 200–1, 202, 203–6, 209  
 Hazard ratio 46, 200–4, 206–7  
   constant 201, 202–3  
   non-constant 201–2  
 Helsinki Declaration (2004) 18  
 Herpes Zoster trials 122–3, 193–4  
 Heterogeneity 92, 232, 236, 241  
   multiplicity 84–6, 87, 88  
 Hierarchy 21, 150–2, 154, 190  
 Historical evidence of sensitivity 182  
 HIV trials 22, 199, 226–7  
 Homogeneity 12, 16, 84–7, 102–4, 160, 227  
   meta-analysis 236, 237, 243  
   survival data 204, 206  
   variance 159, 160  
 Hypotheses 17, 47–56, 95, 97, 99–101, 160  
   meta-analysis 237, 242  
   *see also* Alternative hypotheses; Null hypotheses

Imbalance 102–3, 106, 108, 109–10, 170  
 Inclusion criteria 8, 25, 181, 225, 237, 251  
   intention-to-treat 116–17, 124

Independence 159  
 Independent censoring 208–9, 255  
 Inferences 25–38  
 Intention-to-treat (ITT) 111–18, 122–4, 246, 259  
   missing data 116, 118–22, 125  
   population 116  
 Interim analysis 138, 213–18, 223, 250, 253, 254  
   design 223–6, 246  
   DMCs 219–20, 222  
   multiplicity 148–9, 152–3, 213  
  
 Kaplan–Meier (KM) curves 195–7, 203–4  
   survival data 194, 195–7, 200, 203–4, 209  
   *see also* Median event times; Relative risk  
 Kidney stone trials 229–30  
  
 Last observation carried forward (LOCF) 119–20, 155  
   missing data 119–20, 122  
   regulatory issues 247, 249  
 Least squares 93, 95  
   regression line 93–4  
 Level of effect 129–30, 132  
 Likert scale 24  
 Log hazard rate 205  
 Log hazard ratio 233  
 Log odds ratio 233  
 Log ratios 70  
 Log scale 163–4, 183, 211  
   meta-analysis 233, 234  
   survival data 201, 206, 210  
 Log transformation 163–5, 168, 183, 255  
 Logistic regression 19, 96–7, 104–6, 109, 204–5  
 Logit or logistic transform 97, 164  
 Logrank test 197–9  
 Lower confidence limit 39, 44  
  
 Main effects model 99, 104  
 Mann–Whitney U-test 166–8  
 Mantel–Haenszel (MH) chi-square test 19, 75–6, 79  
 Margins 246, 248, 249  
   equivalence 175–6, 178–9, 182–3, 246  
   non-inferiority margins 176–7, 182–5, 189–91, 278

- Mean absolute deviation 29
- Means 27–8, 32–8, 162, 164, 169, 187
- confidence intervals 39–46, 71
  - covariates 107–8
  - difference between two 44–6, 53
  - equivalence 175, 178
  - interpreting t-tests 62–3
  - normal distribution 30–1
  - notation 29
  - paired t-tests 58–61
  - single 39–44
  - standard error 32–5, 38
  - standard error of difference 35–8
  - statistical significance 141–2, 145
  - survival data 193–4, 207
  - t-test extensions 77
  - transformations 163–4
- Mean-to-mean variation 35
- Median event times 196, 207–8
- Medians 27–8, 30, 46, 211, 258
- non-parametric tests 169
- Meta-analysis 86, 184, 229–43, 246, 256, 260
- regulatory issues 237–8, 240–3, 247, 249
  - see also* Forest plots; Funnel plots
- Minimisation 4, 9–10
- Missing data 118–22, 246, 250, 251, 253, 255–6
- intention-to-treat 116, 118–22, 124
  - multiplicity 148, 158
  - regulatory issues 247–9
- Modified intention-to-treat population 116
- Multi-centre trials 81–9, 91–2, 250, 253
- design 20, 246
  - randomisation 5, 7–9, 81–2, 156
  - regulatory issues 148–9, 155, 247
  - t-test extensions 78
- Multiple regression 94–6, 99
- Multiple sclerosis trials 120, 167–8, 258–60
- Neyman–Pearson Lemma 128
- Noise 15–16, 27, 59, 78, 99
- chi-square test 66–7
  - non-parametric tests 167, 169
  - p*-values 53, 145
  - simple linear regression 93–4
- Non-constant variance 160
- Non-inferiority 17–18, 117, 173–91, 246, 259
- analysis sets 182
  - assay sensitivity 180–2
  - biocreep 186
  - confidence intervals 176–8, 179
  - design 246
  - meta-analysis 232, 241
  - multiplicity 154, 158, 190
  - p*-values 145, 177, 178–80, 187, 190
  - regulatory issues 247, 248
  - sample size 187–9, 191
  - switching between superiority 189–91
- Non-parametric tests 159–71
- Normal distribution 29–32, 41, 66, 167
- Normal probability plot 160–2
- Normality 160–3, 183, 194, 255
- assumptions 159, 160–3, 166, 170
  - transformations 160, 163–4, 166
- Null distribution 65–6, 128, 167
- p*-values 50, 52, 54–5
- Null hypotheses 47, 59, 72, 77, 93, 99, 127–8
- chi-square tests 64, 74
  - equivalence 173, 178–9
  - multiplicity 83, 85
  - non-inferiority 173, 187
  - non-parametric tests 169
  - p*-values 47, 49–50, 53–6, 141, 145
- Number needed to treat (NNT) 67, 69–70, 71, 76, 88
- Observed frequencies (*O*) 64–6, 67, 70, 73
- Odds 67–8, 77, 105
- Odds ratio (OR) 67–8, 71, 76–7, 88, 92, 201
- confidence intervals 46, 70–1, 142
  - logistic regression 104–5
  - meta-analysis 232–3, 234, 238, 239, 241
  - multiplicity 88, 156
- One pivotal study 240, 241–2, 243, 247
- One sample t-test 58
- One-sided confidence intervals 176, 177, 179
- One-sided equivalence 174
- One-sided significance level 215
- One-sided tailed tests 55–6
- One-sided type I error 223
- One-way analysis of variance (one-way ANOVA) 77–9
- Ordered categorical data 19–20, 75–6

Ordinal data 19–20, 23–4, 29, 79, 88, 204  
 chi-square tests 75–6, 77, 79, 79, 88  
 CMH tests 91–2, 109, 204  
 logistic regression 96, 97, 104–6,  
 109, 204  
 treatment benefits 76–7

Ordinal logistic model 97

Osteoporosis trials 22

Outliers 170–1, 251, 256

*p*-values 47–56, 141–2, 144–5, 178–80,  
 255, 259  
 adjusted analyses 94, 96, 97, 104,  
 107, 109  
 ANCOVA 99–100, 102, 109  
 chi-square tests 66–7, 74–5  
 confidence intervals 58, 141–2, 143–5,  
 170, 178–80  
 design 10, 13, 16  
 equivalence 145, 175, 178–80  
 Fisher's exact test 72  
 interim analysis 215, 216  
 interpreting t-tests 61–3  
 meta-analysis 232, 236  
 misinterpretation 144–5  
 multiplicity 83, 85–6, 88, 147, 149, 152,  
 154–7  
 non-inferiority 145, 177, 178–80, 187,  
 190  
 non-parametric tests 167, 169, 170  
 safety 218  
 sample size 53, 127, 129–31, 144, 145,  
 178, 187  
 statistical significance 141–5  
 superiority 173, 180  
 survival data 197, 199, 203, 204, 207  
 t-tests 57–60, 77, 159, 160, 162–4, 170  
 transformations 163–4

Pain trials 18, 24, 122–3, 194

Paired design 13

Paired t-tests 58–61, 62, 79, 132, 164  
 assumptions 159, 168

Pairwise comparisons 78, 79, 80, 148

Parallel groups 12–13, 15, 57, 63, 258

Participant flow 258–9

Patient-to-patient variability 12, 13, 15–16  
 changing parameters 135  
 confidence intervals 44  
 intention-to-treat 126  
 multiplicity 84  
*p*-values 53, 145

paired t-tests 60  
 sampling 26–9, 34, 35  
 standard deviation 28–9, 35  
 t-test extensions 78

Pearson chi-square test 19, 63–6, 67, 71  
 categorical data 73  
 ordinal data 75–6

Per-protocol set 117, 137, 247, 250  
 equivalence 182  
 intention-to-treat 117, 118–19, 126  
 multiplicity 158  
 non-inferiority 182, 188  
 power 137, 140

Phase I trials 220

Phase II trials 220

Phase III trials 225–6, 234–6

Placebos 3–4, 47, 129, 143, 249, 258  
 design 2–4, 6, 17–18, 224  
 dosage studies 79–80  
 meta-analysis 232, 238, 241  
 treatment benefit measures 69

Pocock method 153, 213–15, 223

Polychotomous logistic model 97

Pooling 229–31, 241, 256

Population 26–7, 39–45, 59, 116, 225  
 sample 25–7, 29–33, 38

Positively skewed data 160–1, 163–4, 169,  
 183, 194

Post-baseline data 116, 120

Power 6, 16, 128–31, 144, 223–4, 258  
 ANCOVA 102  
 changing parameters 134–6  
 equivalence 173  
 intention-to-treat 120, 126  
 interim analysis 215–16, 223  
 meta-analysis 231–2  
 multiplicity 85–6, 131, 156  
 non-inferiority 173, 187–8  
 non-parametric tests 170  
 regulatory issues 136–7  
 sample size 127–40, 187–8, 209–11  
 survival data 209–11  
 type II errors 128, 130, 137, 139

Pre-planning and pre-specification 106,  
 251, 253–5  
 covariates 106  
 design 4, 9, 12, 21, 245–7  
 interim analysis 216–17  
 meta-analysis 237–8, 240–2  
 missing data 119, 125  
 multiplicity 157, 158

- non-inferiority 187, 190
  - per-protocol sets 126
  - safety 218
  - sample size 187
  - statistical process 249, 251–5, 257
- Precision 11–12, 24, 232, 246
  - standard errors 35, 37–8, 43
- Presentations 257–60
- Primary endpoints 20–1, 137, 149–52, 174, 181, 187, 249
  - covariates 108
  - design 7, 17, 20–1, 23, 224–5, 226, 245–6
  - interim analysis 214, 223
  - multiplicity 82, 149–52
  - sample size 132, 133–4, 139–40, 187, 209
  - statistical process 250, 254
- Probability 47–56, 147, 216
  - chi-square tests 65, 74, 75
  - Fisher's exact test 72
  - logistic regression 96–7
  - multiplicity 87
  - non-inferiority 189, 190
  - paired t-tests 59
  - power 128, 131, 136
  - survival data 196, 197–8, 203–4
  - see also p-values*
- Proof of concept 17, 22
- Proportional hazards model 204, 205–7, 210–11, 255
- Proportions 29, 38, 45–6
- Protocol 8, 34, 117, 137, 180, 190, 250, 253–5
  - covariates 106
  - DMCs 220
  - intention-to-treat 111, 116, 117, 118–19, 125, 126
  - meta-analysis 231, 236, 237–8, 240–1
  - missing data 118–19, 121, 125
  - multiplicity 149, 151, 152, 155, 157
  - outliers 171
  - sample size 138, 139
  - statistical process 249–50, 253–5, 256
  - violations 8, 111, 220, 247
- Pseudo-centres 82, 88
- Publications 257–60
  - bias 238–40, 259
- Qualitative interactions 87
- Quantile–quantile plots 160–1, 164–5
- Quantitative interactions 87
- Random effects model 234
- Randomisation 4–11, 250
  - baseline testing 109
  - bias 4, 6, 8, 12
  - covariates 107–8
  - design 1–2, 4–11, 12, 13, 226, 245
  - intention-to-treat 111–16, 122–4
  - meta-analysis 229–30, 231
  - publications 259, 260
  - sampling 26, 37
- Ranking 166–7, 168, 169, 170
- Re-analyses 257
- Re-parameterisation 101
- RECIST criteria 19, 24
- Recruitment 3, 8, 115, 180–1, 217–18, 224–5
  - DMCs 220, 222
  - interim analysis 216, 217–18, 223
- Regression 63, 92–7, 102, 142, 259
  - assumptions 159, 163
  - logistic 96–7
  - multiple 94–6
  - simple linear 92–4
  - transformations 164
- Regression towards the mean 107–8
- Regulatory issues 106–8, 136–8, 148–9, 240–3, 247–9, 256–7
  - covariates 106–8, 247–9
  - design 4, 17, 23, 247, 248–9
  - interim analysis 217
  - meta-analysis 237–8, 240–3, 247, 249
  - multiplicity 148–9, 155, 247
  - statistical process 249, 250, 252, 255–7
  - statistical significance 55
- Relative risk (RR) 67, 68–9, 71, 76, 88, 142, 196
  - survival data 196, 203
- Relative risk increase (RRI) 69
- Relative risk reduction (RRR) 67, 69, 71, 76, 88, 196
- Reliability 37–8
- Repeatability 241
- Repeated measure ANOVA 154–5
- Reporting the analysis 252–3
- Residuals 162–3
- Respiratory problem trials 18, 105
- Retrospective analyses 240–1
- Risk ratio 68

Robustness 3, 182, 191, 236, 255–6  
   meta-analysis 236, 237, 241–2  
   non-parametric tests 169  
   survival data 209  
   t-tests 161, 170

Safety sets 125, 250

Safety 218, 250, 253, 256  
   design 2, 4, 6, 11, 16, 18, 21, 223, 225  
   DMCs 219–20, 222  
   intention-to-treat 125  
   interim analysis 218, 223  
   multiplicity 149  
   stopping 214

Salk polio vaccine trial 1–2

Sample distribution 26–7

Sample histogram 26–7

Sample size 25, 32–5, 131–4, 137–40,  
   187–9, 209–11, 223–4  
   adjustment 137–8  
   assumptions 138, 140, 162, 187–8  
   changing parameters 134–6  
   chi-square tests 66, 71, 72, 75–6  
   clinical importance 144  
   confidence intervals 42–4, 46, 187  
   design 5, 12, 15, 16, 223–4, 225–6  
   equivalence 189  
   intention-to-treat 125, 126  
   interim analysis 213, 216, 223  
   multiplicity 85, 138, 153  
   non-inferiority 187–9, 191  
   *p*-values 53, 127, 129–31, 144, 145, 178,  
   187  
   power 127–40, 187–8, 210–11  
   regulatory issues 248  
   reporting calculation 138–40  
   standard deviation 28, 132, 137–8,  
   139–40, 187  
   statistical process 250, 254, 258  
   survival data 138, 209–11  
   t-tests 57, 59, 79, 170  
   type I and type II errors 127–8, 131,  
   138, 140, 187

Sampling 25–38, 39–40  
   distributions 35–6  
   variation 34, 39

Scatter plots 92–4, 98, 100

Schizophrenia trial 119

Scientific method 49

Score data 19–20, 29, 45

Secondary endpoints 21, 123, 151, 231–2,  
   250  
   design 13, 17, 21, 223, 245–6

Sensitivity 117–18, 121, 162, 180–2, 247,  
   255–6  
   adjusted analyses 97, 110  
   design 23  
   intention-to-treat 117–18, 121  
   meta-analysis 241  
   missing data 121  
   multiplicity 148  
   survival data 209  
   *see also* Assay sensitivity

Sequential plan 218

Serious adverse events (SAEs) 218, 221–2,  
   231

Shapiro–Wilks test 162

Signal 15–16, 26–7, 59  
   adjusted analyses 93–4, 99  
   chi-square tests 64, 67  
   non-parametric tests 167, 169  
   *p*-values 52, 53, 55

Signal-to-noise ratio 15–16, 66–7  
   adjusted analyses 99, 104  
   chi-square tests 65, 66–7  
   non-parametric tests 167, 169  
   *p*-values 52, 53–4, 145  
   unpaired t-tests 57

Significance level 55, 127–8, 249  
   adjusted 148, 149–51, 153, 155  
   interim analysis 213–15, 223

Similarity 173, 174

Simple linear regression 92–4, 95–6, 97

Simple randomisation 5

Simpson's Paradox 230

Single-blind trials 4

Square root transformation 164

Standard deviation 28–9, 80, 134–5, 258  
   chi-square tests 66–7, 79  
   confidence intervals 41, 42  
   non-inferiority 187  
   non-parametric tests 167  
   power 137  
   sample size 28, 132, 137–8, 139–40, 187  
   sampling 29, 30–1, 32, 34–5, 37–8  
   t-tests 59, 78–9, 159, 160

Standard errors 35–8, 43–4, 66, 184  
   adjusted analyses 93, 95, 97, 99, 101–2,  
   104  
   confidence intervals 35, 38, 42, 43–4, 45,  
   70–1

- difference of two means 53
  - meta-analysis 232–3
  - non-parametric tests 167, 169
  - p*-values 53
  - survival data 196, 197
  - t*-tests 59, 160
- Standardisation 162
- Statistical analysis plan (SAP) 157, 250–1, 252, 254–5
  - covariates 106
  - missing data 125
  - multiplicity 89
- Statistical significance 55, 137, 141–5
  - equivalence 181
  - interim analysis 215–17
  - meta-analysis 232, 236, 238, 241–2
  - multiplicity 84, 86, 147–8, 150–2, 154, 158
  - non-inferiority 181, 189
  - non-parametric tests 167
  - transformations 164
- Stepwise regression 96, 97, 108
- Stopping rules 213–17, 218, 222, 223, 248
- Stratification 7–8, 91–2, 103, 108, 109, 204
  - design 4, 7–10
- Stroke trials 21, 133, 150, 223, 224
- Study-to-study variation 229
- Subgroups 155–7, 206, 231–2, 253, 254
  - ANCOVA 103–4
  - see also* Treatment-by-covariate interactions
- Submission 256–7
- Success/failure classification 119, 120
- Superiority 17–18, 117, 154, 246, 247
  - equivalence and non-inferiority 173, 180, 182, 188–9
  - switching between non-inferiority 189–91
- Surrogate endpoints 21–2, 249
- Survival curves 194, 195–8, 200, 202, 203–4, 210
- Survival data 193–211, 255
  - accelerated failure time model 207–8
  - adjusted analyses 204–8
  - censoring 193–4, 208–9
  - Gehan–Wilcoxon tests 197–9
  - hazard rate 200–1
  - hazard ratio 200–3
  - Kaplan–Meier curves 195, 203–4
  - logrank test 197–9
  - median event times 197
  - proportional hazards model 204–6
  - relative risk 196
  - sample size 209–11
- t*-distribution 53–4, 57–8, 60, 160
- t*-tests 19, 57–61, 77–9, 159
  - assumptions 159, 160–3, 168, 170
  - extensions 77–9
  - interpretation 61–3
  - transformations 163–6
  - two sample 52, 57, 140, 145
  - see also* Paired *t*-tests; Unpaired *t*-tests
- Test of significance 55
- Test statistic 50, 52, 53–5, 74
- Time-dependent covariates 107
- Time-to-event data 122–4, 255, 258, 259
- Transformations 160, 163–6, 169, 170, 171
  - see also* Log transformation
- Treatment benefit measures 67–71, 76–7
- Treatment-by-centre interactions 84–6, 87, 92, 236, 248
  - ANOVA 84–8
- Treatment-by-covariate interactions 99–101, 102–4, 248
  - ANCOVA 100
  - logistic regression 105–6
  - multiplicity 155–6
  - non-parametric tests 170
- Treatment-by-study interactions 236
- Treatment effects/differences 67–71, 84–7, 91–2
  - ANCOVA 97–104, 109–10
  - changing parameters 134
  - design 7, 224–5, 246
  - logistic regression 104–6
  - meta-analysis 230, 232–3, 238, 240–2
  - p*-values 141, 144–5
  - power 128–31
  - pre-planning 255
  - sample size 138
  - standard error 37–8
  - survival data 197–9, 201, 204, 206, 208
  - t*-tests 59, 61–3
  - treatment benefit measures 67–71, 76–7
- True difference 187
- True mean 29, 33, 35, 37, 40–1, 194
- True standard deviation 29
- Two pivotal trial rule 241–3
- Two-sample *t*-test 52, 57, 140, 145

Two-sided  $p$ -value 169  
 Two-sided significance levels 223  
 Two-sided tests 55–6  
 Two-sided type I error 241  
 Two-tailed  $p$ -values 215  
 Two-tailed tests 55–6, 130, 135, 138  
 Two-way analysis of variance (ANOVA)  
   82–5, 91, 102, 109  
 Two, one-sided tests approach 179  
 Type I errors 127–8, 131, 147, 223–5, 241,  
   248  
   DMCs 219  
   interim analysis 213, 214, 217, 223  
   multiplicity 147–9, 152–3, 154  
   non-inferiority 187  
    $p$ -values 49, 56, 178  
   safety 218  
   sample size 128, 131, 138, 140, 187  
   statistical process 250, 258  
 Type II errors 127–8, 136–7, 258  
   multiplicity 149  
    $p$ -values 49, 178  
   power 128, 130, 137, 139  
   sample size 127–8, 187  
 Unblinding 181, 249, 251–2, 254–5, 257  
   design 6, 21, 223–5, 245  
   DMCs 220–1  
 Unequal randomisation 4, 6–7, 134  
 Unpaired  $t$ -tests 57–8, 60, 129, 132–3  
   ANCOVA 97, 99, 102  
   assumptions 159, 160–3, 168

  extensions 78  
   interpretation 62  
    $p$ -values 52, 141–2  
   sample size 132–3, 211  
   transformations 163–4  
   type I and type II errors 127  
 Unrestricted randomisation 4, 5  
 Upper confidence limit 39, 44  
 Validation plan 251, 252  
 Variable selection methods 108  
 Variance 28, 31, 160, 255  
   homogeneity 159, 160  
   sample size 135, 140  
   transformations 164  
 Visual Analogue Scale (VAS) 24  
 Washout period 14, 181  
 Weighting 84, 87, 233  
 Welch's approximation 157, 160  
 Wilcoxon rank sum test 166–7  
 Wilcoxon signed rank test 168–9  
 Withdrawals 3, 139  
   intention-to-treat 111, 123–4,  
     125–6  
   missing data 119, 120, 121  
   survival data 194, 208–9  
 Within-patient design 13, 14, 58, 78–9,  
   132  
 Worst case/best case 119, 120, 122,  
   209



